Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AstraZeneca Crestor 10 Mg Starting Dose Priced At 12% Discount To Lipitor

  • News

Executive Summary

AstraZeneca's Crestor will be priced at a 12% discount to the average weighted cost per day of Pfizer's Lipitor

You may also be interested in...



Crestor Impact Review To Precede Mass. Medicaid Preferred Statin Decision

Massachusetts Medicaid will assess the market impact of AstraZeneca's Crestor (rosuvastatin) before selecting a preferred statin for the program

Crestor Impact Review To Precede Mass. Medicaid Preferred Statin Decision

Massachusetts Medicaid will assess the market impact of AstraZeneca's Crestor (rosuvastatin) before selecting a preferred statin for the program

Lipitor Weathers Crestor Launch; Lancet Weighs In On Pfizer’s Side

The early returns in the Lipitor versus Crestor marketing battle are running heavily in favor of Pfizer

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

See All
UsernamePublicRestriction

Register

PS042307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By